BOTOX binds to specific receptors at the nerve endings, blocking the release of the neurotransmitter acetylcholine. Without acetylcholine, nerve signals telling the muscle to contract or spasm are blocked. The effects of a single injection typically last up to three to four months. We believe BOTOX has the potential for many more therapeutic uses that will enhance patients’ quality of life as scientists and physicians recognize and harness its broad applicability. Allergan is committed to identifying those unmet clinical needs and developing BOTOX to its full potential in serving our patient populations. outlook: from physical conditions to social obstacles With the BOTOX molecule, Allergan accounts for approximately 90 percent of the emerging, worldwide neuromodulator market. We have filed a new drug application for this chronic and debilitating disease in the United States and anticipate receiv- ing approval in 2004. In treating hyperhidrosis, BOTOX is believed to temporarily block the nerves that stimulate sweat glands. Recent studies have shown that BOTOX relieved hyperhidrosis for an average of seven months. For 28 percent of the participants, the relief (or lack of sweating) lasted for over one year. Hyperhidrosis can create significant obstacles in a person’s daily living and social encounters. As William “Butch” Weinrich tells it, hyperhidrosis affects the most basic decisions, includ- ing what clothes to wear. “You don’t wear dark clothing, which shows underarm stains,” says the 47-year-old father of two. “White shirts are out. And you can’t wear T-shirts more than a few times.” In 2003, Allergan gained European Commission approval for the use of BOTOX in treating axillary hyperhidrosis, or exces- sive underarm sweating. 